tiprankstipranks
Trending News
More News >
Immix Biopharma, Inc. (IMMX)
:IMMX
US Market

Immix Biopharma (IMMX) Income Statement

Compare
184 Followers

Immix Biopharma Income Statement

Last quarter (Q3 2025), Immix Biopharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Immix Biopharma's net income was $-7.59M. See Immix Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 22.67M$ 16.14M$ 8.22M$ 1.35M$ 453.85K
Depreciation and Amortization
$ 115.39K$ 5.47K$ 2.13K$ 2.47K$ 2.32K
EBITDA
$ -22.56M$ -16.14M$ -8.22M$ -24.20M$ -451.53K
Operating Income
$ -22.67M$ -16.14M$ -8.22M$ -1.35M$ -453.85K
Other Income/Expenses
$ 1.02M$ 572.01K$ -497.00$ -23.03M$ -676.46K
Pretax Income
$ -21.66M$ -15.57M$ -8.22M$ -24.38M$ -1.13M
Net Income
$ -21.61M$ -15.43M$ -8.23M$ -24.38M$ -1.15M
Per Share Metrics
Basic EPS
$ -0.76$ -0.89$ -0.59$ -6.64$ -0.15
Diluted EPS
$ -0.76$ -0.89$ -0.59$ -6.64$ -0.15
Weighted Average Shares Outstanding
28.29M 17.34M 13.89M 3.67M 7.77M
Weighted Average Shares Outstanding (Diluted)
28.29M 17.34M 13.89M 3.67M 7.77M
Currency in USD

Immix Biopharma Earnings and Revenue History